DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Receives Average Recommendation of "Hold" from Analysts

Key Points

• Analysts maintain a “Hold” consensus: Of 15 firms covering DENTSPLY SIRONA, nine rate it Hold, while three rate it Sell and three rate it Buy. The average 12-month price target is $13.54.
• Q2 earnings beat expectations: Adjusted EPS came in at $0.52 versus a $0.35 consensus, and revenue reached $898 million. Improved margins and growth in the Wellspect business helped offset softer core dental demand.
• Sales outlook remains cautious: Q2 revenue declined 4.1% year over year, while 2026 revenue guidance of $3.5 billion-$3.6 billion is below the $3.6 billion consensus midpoint. Full-year adjusted EPS guidance was maintained at $1.40-$1.50.

DENTSPLY SIRONA Inc. (NASDAQ:XRAY - Get Free Report) has been assigned a consensus recommendation of "Hold" from the fifteen research firms that are presently covering the firm, Marketbeat reports. Three investment analysts have rated the stock with a sell rating, nine have issued a hold rating and three have issued a buy rating on the company. The average 1 year price target among brokerages that have covered the stock in the last year is $13.5385.

XRAY has been the topic of a number of recent research reports. Barclays dropped their target price on DENTSPLY SIRONA from $12.00 to $9.00 and set an "underweight" rating on the stock in a report on Thursday, June 4th. Mizuho decreased their price target on DENTSPLY SIRONA from $16.00 to $14.00 and set a "neutral" rating for the company in a report on Wednesday, May 6th. BMO Capital Markets reissued a "market perform" rating and issued a $13.00 price target on shares of DENTSPLY SIRONA in a research report on Friday. Piper Sandler raised their price target on shares of DENTSPLY SIRONA from $13.00 to $14.00 and gave the company a "neutral" rating in a research report on Wednesday, July 29th. Finally, UBS Group decreased their price target on DENTSPLY SIRONA from $18.00 to $17.00 and set a "buy" rating for the company in a research report on Thursday, May 7th.

Key DENTSPLY SIRONA News

Here are the key news stories impacting DENTSPLY SIRONA this week:

• Positive Sentiment: Adjusted earnings exceeded expectations: Q2 EPS was $0.52, above analyst estimates ranging from $0.35 to $0.36 and matching the year-ago result. Revenue of $898 million also surpassed the roughly $890 million consensus. Dentsply International Beats Q2 Earnings and Revenue Estimates
• Positive Sentiment: Margins improved: Management highlighted better margins during the quarter, helping offset softer demand and supporting the earnings beat. The Wellspect business was a key sales-growth contributor. XRAY Stock Falls Despite Q2 Earnings Beat, Wellspect Drives Sales
• Neutral Sentiment: Full-year EPS guidance was maintained: DENTSPLY SIRONA reiterated 2026 adjusted EPS guidance of $1.40 to $1.50, which brackets the approximately $1.42 analyst consensus. DENTSPLY SIRONA Second-Quarter 2026 Results
• Negative Sentiment: Sales declined year over year: Q2 revenue fell 4.1%, as weakness in the company’s core dental business outweighed growth at Wellspect. This suggests that broader dental-market demand and utilization remain pressured. XRAY Stock Falls Despite Q2 Earnings Beat, Wellspect Drives Sales
• Negative Sentiment: Revenue guidance was cautious: The company forecast 2026 revenue of $3.5 billion to $3.6 billion, with the midpoint below the $3.6 billion consensus estimate. Investors appear to be prioritizing the weak organic-sales trend and outlook over the quarterly EPS beat.

DENTSPLY SIRONA Trading Down 8.0%

NASDAQ:XRAY opened at $12.12 on Friday. The company has a debt-to-equity ratio of 1.52, a current ratio of 1.53 and a quick ratio of 0.98. DENTSPLY SIRONA has a one year low of $9.40 and a one year high of $14.86. The company has a market cap of $2.43 billion, a PE ratio of -4.41, a PEG ratio of 1.57 and a beta of 0.85. The firm has a 50-day moving average of $11.77 and a 200-day moving average of $11.89.

DENTSPLY SIRONA (NASDAQ:XRAY - Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $0.52 earnings per share for the quarter, beating the consensus estimate of $0.35 by $0.17. The business had revenue of $898.00 million for the quarter, compared to analysts' expectations of $889.93 million. DENTSPLY SIRONA had a negative net margin of 14.99% and a positive return on equity of 20.74%. The firm's revenue for the quarter was down 4.1% compared to the same quarter last year. During the same quarter last year, the firm earned $0.52 EPS. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. As a group, equities research analysts expect that DENTSPLY SIRONA will post 1.42 EPS for the current fiscal year.

Insider Buying and Selling at DENTSPLY SIRONA

In related news, Director Brian T. Gladden bought 9,985 shares of the company's stock in a transaction on Monday, June 15th. The shares were purchased at an average cost of $10.02 per share, for a total transaction of $100,049.70. Following the completion of the purchase, the director directly owned 61,849 shares in the company, valued at $619,726.98. The trade was a 19.25% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Brian P. Mckeon purchased 10,000 shares of the stock in a transaction that occurred on Friday, June 12th. The stock was bought at an average cost of $10.12 per share, for a total transaction of $101,200.00. Following the acquisition, the director directly owned 10,000 shares in the company, valued at $101,200. This trade represents a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders acquired 35,160 shares of company stock worth $351,179 in the last quarter. 0.46% of the stock is currently owned by company insiders.

Institutional Trading of DENTSPLY SIRONA

Several hedge funds have recently made changes to their positions in the company. Alpine Woods Capital Investors LLC purchased a new position in shares of DENTSPLY SIRONA during the 2nd quarter valued at $317,000. Citizens Financial Group Inc. RI bought a new position in shares of DENTSPLY SIRONA during the 2nd quarter worth $118,000. BlackRock Inc. purchased a new stake in DENTSPLY SIRONA in the 2nd quarter worth about $283,405,000. Pallas Capital Advisors LLC purchased a new stake in DENTSPLY SIRONA in the 2nd quarter worth about $422,000. Finally, Deutsche Bank AG bought a new stake in DENTSPLY SIRONA in the 2nd quarter valued at about $2,837,000. 95.70% of the stock is currently owned by institutional investors.

About DENTSPLY SIRONA

Dentsply Sirona Inc NASDAQ: XRAY is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company's product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source